Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 32 of 75 for:    AMPHETAMINE AND DEXTROAMPHETAMINE

A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02144415
Recruitment Status : Completed
First Posted : May 22, 2014
Last Update Posted : August 15, 2014
Sponsor:
Information provided by (Responsible Party):
Euthymics BioScience, Inc. ( Neurovance, Inc. )

Brief Summary:
This single-center study will be a single-dose, randomized, double-blind, placebo- and active-controlled crossover study with a single inpatient treatment visit. The abuse potential of single oral doses of EB-1020 IR (400 mg, 800 mg) will be compared with that of placebo and d-amphetamine (20 mg, 40 mg; active control) in healthy recreational stimulant users. Subjects will participate in a medical Screening visit (Visit 1), one 4-day inpatient Qualification Phase (Visit 2), one 11-day inpatient Treatment Phase (Visit 3), and a safety Follow-up visit (Visit 4).

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug Users Drug: EB-1020 400 mg Drug: EB-1020 800 mg Drug: lisdexamfetamine 150 mg Drug: d-amphetamine 40 mg Drug: Placebo Phase 1

Detailed Description:

Subjects will be randomized to 1 of 10 treatment sequences according to a two 5 x 5 William squares design. To maintain blinding, subjects will be required to ingest eight capsules with approximately 240 mL water on each study drug administration day.

Serial pharmacodynamic (PD) evaluations will be conducted up to 24 hours after each study drug administration. Pharmacokinetic (PK) samples will be obtained to confirm exposure to EB-1020. Safety monitoring will include recording of adverse events (AEs), regular assessments of vital signs measurements, 12-lead electrocardiogram (ECG) findings, and continuous telemetry monitoring for at least 3 hours after study drug administration.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : May 2014
Actual Primary Completion Date : July 2014
Actual Study Completion Date : July 2014

Arm Intervention/treatment
Experimental: EB-1020 400 mg
EB-1020 400 mg, administered as four 100-mg IR capsules and 4 matching placebo capsules
Drug: EB-1020 400 mg
4 x EB-1020 100-mg capsules, and 4 matching placebo capsules

Experimental: EB-1020 800 mg
EB-1020 800 mg, administered as eight 100-mg IR capsules
Drug: EB-1020 800 mg
8 x EB-1020 100-mg capsules

Active Comparator: lisdexamfetamine 150 mg
lisdexamfetamine 150 mg, administered as 3 capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 matching placebo capsules
Drug: lisdexamfetamine 150 mg
3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules

Active Comparator: d-amphetamine 40 mg
d-amphetamine 40 mg, administered as 4 capsules, each containing two 5-mg d-amphetamine tablets and 4 matching placebo capsules
Drug: d-amphetamine 40 mg
4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules

Placebo Comparator: Placebo
Placebo, administered as 8 matching placebo capsules
Drug: Placebo
8 x matching placebo capsules




Primary Outcome Measures :
  1. Maximum effect (Emax) on Drug Liking visual analog scale (VAS) [ Time Frame: within 24 hours post-dose ]
    Drug liking VAS is one of the measures of balance of effects that assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of "neither like nor dislike" (score of 50 mm), on the left with "strong disliking" (score of 0 mm) and on the right with "strong liking" (score of 100 mm).


Secondary Outcome Measures :
  1. Drug Liking VAS (minimum effect [Emin] and time-averaged area under the effect curve to 12 hours after study drug administration [TA_AUE]) [ Time Frame: within 24 hours post-dose ]
    Drug liking VAS is one of the measures of balance of effects that assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of "neither like nor dislike" (score of 50 mm), on the left with "strong disliking" (score of 0 mm) and on the right with "strong liking" (score of 100 mm).

  2. Overall Drug Liking VAS (Emax/Emin) [ Time Frame: within 24 hours post-dose ]
    Overall drug liking VAS is one of the measures of balance of effects that assesses the participant's global perception of drug liking (that is, effects over the whole course of the drug experience including any carryover effects). A 100 mm bipolar VAS is used to assess response based on a score ranging from 0 mm to 100 mm (0 mm = "strong disliking", 50 mm= "neither like nor dislike", and 100 mm= "strong liking").

  3. Take Drug Again VAS (Emax) [ Time Frame: within 24 hours post-dose ]
    Take drug again VAS is one of the measures of balance of effects. It is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100 mm bipolar VAS with score ranging from 0 mm to 100 mm (score of 0 mm = "definitely not", 50 mm = "do not care", and 100 mm = "definitely so").

  4. High VAS (Emax and TA_AUE) [ Time Frame: within 24 hours post-dose ]
    High VAS is one of the measures of positive effects that assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 = definitely so).

  5. Good Effects VAS (Emax and TA_AUE) [ Time Frame: within 24 hours post-dose ]
    Good drug effects VAS is one of the measures of positive effects that assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 mm= definitely so).

  6. Bad Effects VAS (Emax and TA_AUE) [ Time Frame: within 24 hours post-dose ]
    Bad effects VAS is one of the measures of negative effects that assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 mm= definitely so).

  7. Nausea VAS (Emax and TA_AUE) [ Time Frame: within 24 hours post-dose ]
    Nausea VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm).

  8. ARCI-A scale (Emax and TA_AUE) [ Time Frame: within 24 hours post-dose ]
    ARCI-A is measure of other stimulant effects. It is a set of 13 questions in which each question contributes to total score. Participants select 'False' / 'True' for response. One point given for each response that agrees with scoring direction, true items receive score of 1 if answer 'True', false items receive score of 1 if answer 'False'. No points if answer is opposite to scoring direction. Score range: 0 to 13, higher score indicated higher other subjective effects.

  9. ARCI-BG scale (Emax and TA_AUE) [ Time Frame: within 24 hours post-dose ]
    ARCI-BG is measure of other subjective effects. It is a set of 13 questions in which each question contributes to total score. Participants select 'False' / 'True' for response. One point given for each response that agrees with scoring direction, true items receive score of 1 if answer 'True', false items receive score of 1 if answer 'False'. No points if answer is opposite to scoring direction. Score range: 0 to 13, higher score indicated higher other subjective effects.

  10. Alertness/Drowsiness VAS (Emax and TA_AUE) [ Time Frame: within 24 hours post-dose ]
    Alertness/Drowsiness VAS is one of the measures of sedative effects. It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of "neither drowsy nor alert" (score of 50 mm), on the left with "very drowsy" (score of 0 mm) and on the right with "very alert" (score of 100 mm).

  11. Agitation/Relaxation VAS (Emax and TA_AUE) [ Time Frame: within 24 hours post-dose ]
    Agitation/Relaxation VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm).

  12. Any Effects VAS (Emax and TA_AUE) [ Time Frame: within 24 hours post-dose ]
    Any drug effects VAS is one of the measures of other subjective effects. It assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 mm= definitely so).

  13. Drug Similarity VAS (score at 12 hours after study drug administration) [ Time Frame: within 24 hours post-dose ]
    Drug similarity VAS is one of the measures of other subjective effects. It assesses the similarity of the drug recently received by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= not at all similar) to 'extremely' (score of 100 mm= very similar). Recently received drugs were compared with placebo, benzodiazepines, codeine/morphine, Tetrahydrocannabinol (THC), pseudoephedrine.

  14. Safety and tolerability of EB-1020 as assessed by AEs [ Time Frame: Up to 6 weeks ]
  15. Safety and tolerability of EB-1020 by laboratory assessments [ Time Frame: Up to 6 weeks ]
  16. Safety and tolerability of EB-1020 as assessed by 12-lead ECGs [ Time Frame: Up to 6 weeks ]
  17. Safety and tolerability of EB-1020 as assessed by vital signs [ Time Frame: Up to 6 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subjects must be healthy male nondependent recreational drug users
  2. Subjects must be 18 to 55 years old, inclusive.
  3. Subjects must have greater than or equal to 10 lifetime nontherapeutic experiences with central nervous system (CNS) stimulants (e.g., amphetamines, cocaine, methylphenidate), greater than or equal to 1 nontherapeutic use of prescription stimulants within the 12 months prior to Screening, and greater than or equal to 1 nontherapeutic use of a CNS stimulant within the 12 weeks prior to Screening.

Exclusion Criteria:

  1. Subjects that are deemed medically unsuitable or unlikely to comply with the study protocol for any reason.
  2. Subjects who do not pass Qualification Phase criteria to be eligible for the Treatment Phase.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02144415


Locations
Layout table for location information
United States, Kansas
Vince and Associates Clinical Research, Inc.
Overland Park, Kansas, United States, 66212
Sponsors and Collaborators
Neurovance, Inc.

Layout table for additonal information
Responsible Party: Neurovance, Inc.
ClinicalTrials.gov Identifier: NCT02144415     History of Changes
Other Study ID Numbers: EB-1020 IR-103
First Posted: May 22, 2014    Key Record Dates
Last Update Posted: August 15, 2014
Last Verified: August 2014
Keywords provided by Euthymics BioScience, Inc. ( Neurovance, Inc. ):
abuse liability
recreational drug user
stimulant
d-amphetamine
ADHD
Additional relevant MeSH terms:
Layout table for MeSH terms
Amphetamine
Dextroamphetamine
Lisdexamfetamine Dimesylate
Central Nervous System Stimulants
Physiological Effects of Drugs
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors